Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rachna Raman

Internal Medicine Mechanicsville, VA Medical Doctor

NPI 1710183710 CMS profile 525848

8266 Atlee Rd Ste 219, Mechanicsville, VA 23116

Open in the dashboard

General payments

$3,651

31 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$42 paid to institutions, not to them · program year 2021

Through program year 2025, Rachna Raman of Mechanicsville, VA is reported in the CMS Open Payments database as having received $3,651 across 31 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $42 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 86th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $122 4
2023 General $507 20
2022 General $47 2
2021 General $2,950 3
2019 General $25 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rachna Raman
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Rachna Raman were reported at $122. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Rachna Raman Internal Medicine median Middle half National median
2019 $25 $159 $48–$570 $163
2020 $0 $119 $33–$402 $114
2021 $2,950 $135 $37–$521 $132
2022 $47 $141 $42–$496 $149
2023 $507 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $122 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Bayer HealthCare Pharmaceuticals Inc. $1,713 1 payment
  2. Exelixis Inc. $1,225 1 payment
  3. Astellas Pharma US Inc $124 2 payments
  4. Caris MPI, Inc. $92 3 payments
  5. Seattle Genetics, Inc. $73 4 payments
  6. Pfizer Inc. $65 3 payments
  7. Novartis Pharmaceuticals Corporation $60 2 payments
  8. Eisai Inc. $44 2 payments
  9. AstraZeneca Pharmaceuticals LP $42 2 payments
  10. BeiGene USA, Inc. $37 2 payments
  11. Other $177 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $1,713 1 payment
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,225 1 payment
  3. Food and Beverage $511 23 payments
  4. Education $202 6 payments
Products named General payments · program years 2019–2025
  1. Xofigo $1,713 1 payment
  2. CABOMETYX $1,225 1 payment
  3. MI CANCER SEEK $92 3 payments
  4. KISQALI $60 2 payments
  5. PIQRAY $60 2 payments
  6. ADCETRIS $51 3 payments
  7. Lenvima $44 2 payments
  8. BRUKINSA $37 2 payments
  9. IBRANCE $31 1 payment
  10. OGIVRI $26 1 payment
  11. Other $321 16 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

672

Median for Hematology-Oncology: 604

Drug cost

$3,618,883

Median for Hematology-Oncology: $1,306,514

Branded share of claims

40.8%

Median for Hematology-Oncology: 31.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Pomalyst Pomalidomide Brand 48 $1,109,334
Lenalidomide Generic 47 $682,252
Imbruvica Ibrutinib Brand 41 $396,662
Calquence Acalabrutinib Maleate Brand 30 $387,743
Cabometyx Cabozantinib S-Malate Brand 15 $357,328
Tagrisso Osimertinib Mesylate Brand 13 $334,403
Revlimid Lenalidomide Brand 15 $216,393
Brukinsa Zanubrutinib Brand 12 $83,119
Xarelto Rivaroxaban Brand 23 $24,648
Eliquis Apixaban Brand 23 $18,941

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$73,244

Medicare's payments for the services billed

Medicare patients

384

Average age 75

Services billed

889

191 women, 193 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 56%
Arthritis 47%
Ischemic heart disease 34%
Chronic kidney disease 33%
Diabetes 32%
Heart failure 26%
Atrial fibrillation 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

31 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record